Literature DB >> 22034870

CCR5 antagonism in HIV infection: current concepts and future opportunities.

Timothy J Wilkin1, Roy M Gulick.   

Abstract

CCR5 antagonists inhibit HIV-1 entry by blocking the interaction of HIV-1 with the CCR5 cellular receptor. In patients with established HIV-1 infection, some viral strains use an alternative coreceptor for HIV-1 entry, CXCR4; CCR5 antagonists are not effective in patients harboring these viral strains. Coreceptor tropism testing of viral strains in an individual patient is necessary prior to treating with a CCR5 antagonist. There is one CCR5 antagonist, maraviroc, that is FDA-approved for treatment of HIV-1 infection. This drug is used most commonly for the treatment of HIV-1 infection in patients who have failed other antiretroviral regimens. In addition to virologic effects, CCR5 antagonists are under investigation for immune-modulating effects and for HIV-1 prevention. Ongoing research will further elucidate the role of CCR5 antagonists in combating HIV disease.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22034870      PMCID： PMC3298858          DOI： 10.1146/annurev-med-052010-145454

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  50 in total

1.  Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Authors:  Jeffrey M Jacobson; Jacob P Lalezari; Melanie A Thompson; Carl J Fichtenbaum; Michael S Saag; Barry S Zingman; Paul D'Ambrosio; Nancy Stambler; Yakov Rotshteyn; Andre J Marozsan; Paul J Maddon; Stephen A Morris; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Authors:  Timothy J Wilkin; Mathew Bidwell Goetz; Robert Leduc; Gail Skowron; Zhaohui Su; Ellen S Chan; Jayyant Heera; Doug Chapman; John Spritzler; Jacqueline D Reeves; Roy M Gulick; Eoin Coakley
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

3.  Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Authors:  Timothy J Wilkin; Zhaohui Su; Amy Krambrink; Jianmin Long; Wayne Greaves; Robert Gross; Michael D Hughes; Charles Flexner; Paul R Skolnik; Eoin Coakley; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes; Roy M Gulick
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.

Authors:  Ronald S Veazey; Thomas J Ketas; Jason Dufour; Terri Moroney-Rasmussen; Linda C Green; P J Klasse; John P Moore
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

5.  CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Authors:  Olga Latinovic; Marvin Reitz; Nhut M Le; James S Foulke; Gerd Fätkenheuer; Clara Lehmann; Robert R Redfield; Alonso Heredia
Journal:  Virology       Date:  2011-01-12       Impact factor: 3.616

6.  The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.

Authors:  Timothy J Wilkin; Heather R Ribaudo; Allan R Tenorio; Roy M Gulick
Journal:  HIV Clin Trials       Date:  2010 Nov-Dec

7.  Hepatic safety and tolerability in the maraviroc clinical development program.

Authors:  Ayman Ayoub; Sam Alston; James Goodrich; Jayvant Heera; Andy I M Hoepelman; Jacob Lalezari; Mary Mchale; Mark Nelson; Elna van der Ryst; Howard Mayer
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

8.  Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.

Authors:  Kevin C Brown; Kristine B Patterson; Stephanie A Malone; Nicholas J Shaheen; Heather M Asher Prince; Julie B Dumond; Melissa B Spacek; Paris E Heidt; Myron S Cohen; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2011-05-15       Impact factor: 5.226

9.  Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Authors:  Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

10.  Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

Authors:  C Preston Neff; Thomas Ndolo; Apurva Tandon; Yuichiro Habu; Ramesh Akkina
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240
View more
  31 in total

Review 1.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

2.  CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.

Authors:  Samantha J Westrop; Graeme Moyle; Akil Jackson; Mark Nelson; Sundhiya Mandalia; Nesrina Imami
Journal:  Mol Med       Date:  2012-10-24       Impact factor: 6.354

3.  Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.

Authors:  Joshua F Emory; Lauren A Seserko; Mark A Marzinke
Journal:  Clin Chim Acta       Date:  2014-02-19       Impact factor: 3.786

4.  A GxxxG-like motif within HIV-1 fusion peptide is critical to its immunosuppressant activity, structure, and interaction with the transmembrane domain of the T-cell receptor.

Authors:  Omri Faingold; Tomer Cohen; Yechiel Shai
Journal:  J Biol Chem       Date:  2012-08-07       Impact factor: 5.157

5.  Intracellular allosteric antagonism of the CCR9 receptor.

Authors:  Christine Oswald; Mathieu Rappas; James Kean; Andrew S Doré; James C Errey; Kirstie Bennett; Francesca Deflorian; John A Christopher; Ali Jazayeri; Jonathan S Mason; Miles Congreve; Robert M Cooke; Fiona H Marshall
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

6.  Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5.

Authors:  Massimiliano Secchi; Lia Vassena; Sébastien Morin; Dominique Schols; Luca Vangelista
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

Review 7.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

8.  The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

Authors:  Ian McGowan; Timothy Wilkin; Raphael J Landovitz; Chunyuan Wu; Ying Chen; Mark A Marzinke; Craig W Hendrix; Paul Richardson; Susan H Eshleman; Adriana Andrade; Wairimu Chege; Peter L Anderson; Marybeth McCauley; Jason Farley; Kenneth H Mayer; Peter Anton; Rhonda M Brand; Ross D Cranston; Roy Gulick
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

Review 9.  G protein-coupled receptors--recent advances.

Authors:  Dorota Latek; Anna Modzelewska; Bartosz Trzaskowski; Krzysztof Palczewski; Sławomir Filipek
Journal:  Acta Biochim Pol       Date:  2012-12-18       Impact factor: 2.149

Review 10.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.